IN2014DN06781A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06781A
IN2014DN06781A IN6781DEN2014A IN2014DN06781A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A IN 6781DEN2014 A IN6781DEN2014 A IN 6781DEN2014A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A
Authority
IN
India
Prior art keywords
salt
salts
cushing
aromatase
pyrrolo
Prior art date
Application number
Inventor
Paul Sutton
Eric Loeser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN06781A publication Critical patent/IN2014DN06781A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Abstract

The invention relates to a phosphate salt or a nitrate salt of 4 (R) 6 7 dihydro 5H pyrrolo[l 2 c]imidazol 5 yl 3 fluoro benzonitrile having following formula: especially in crystalline form and specific forms of these salts as well as related invention embodiments. The salts and salt forms allow for the prophylactic and/or therapeutic treatment of aldosterone synthase and/or aromatase mediated diseases or disorders such as Cushing s disease.
IN6781DEN2014 2012-01-17 2013-01-15 IN2014DN06781A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17
PCT/US2013/021521 WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor

Publications (1)

Publication Number Publication Date
IN2014DN06781A true IN2014DN06781A (en) 2015-05-22

Family

ID=47604250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6781DEN2014 IN2014DN06781A (en) 2012-01-17 2013-01-15

Country Status (41)

Country Link
US (2) US9334276B2 (en)
EP (1) EP2804863B1 (en)
JP (1) JP5749410B2 (en)
KR (2) KR20140141687A (en)
CN (1) CN104039793B (en)
AP (1) AP2014007762A0 (en)
AR (1) AR089728A1 (en)
AU (1) AU2013209952B2 (en)
BR (1) BR112014017260A8 (en)
CA (1) CA2863339C (en)
CL (1) CL2014001863A1 (en)
CO (1) CO7000775A2 (en)
CR (1) CR20140345A (en)
CU (1) CU20140086A7 (en)
CY (1) CY1117914T1 (en)
DK (1) DK2804863T3 (en)
EA (1) EA026232B1 (en)
ES (1) ES2564143T3 (en)
GT (1) GT201400155A (en)
HK (1) HK1198536A1 (en)
HR (1) HRP20160178T1 (en)
HU (1) HUE026984T2 (en)
IL (1) IL233541B (en)
IN (1) IN2014DN06781A (en)
JO (1) JO3137B1 (en)
MA (1) MA35858B1 (en)
MX (1) MX2014008686A (en)
NZ (1) NZ626277A (en)
PE (1) PE20142358A1 (en)
PH (1) PH12014501638B1 (en)
PL (1) PL2804863T3 (en)
RS (1) RS54589B1 (en)
SG (1) SG11201404061YA (en)
SI (1) SI2804863T1 (en)
SM (1) SMT201600083B (en)
TN (1) TN2014000256A1 (en)
TW (1) TWI609869B (en)
UA (1) UA114803C2 (en)
UY (1) UY34576A (en)
WO (1) WO2013109514A1 (en)
ZA (1) ZA201404314B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58234B1 (en) * 2010-01-14 2019-03-29 Novartis Ag Use of an adrenal hormone-modifying agent
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EA033685B1 (en) * 2014-07-07 2019-11-15 Novartis Ag Pharmaceutical dosage forms
US10556869B2 (en) 2015-01-29 2020-02-11 Novartis Ag Process for the production of condensed imidazolo derivatives
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
US10822332B2 (en) * 2016-10-27 2020-11-03 Damian Pharma Ag Aldosterone synthase inhibitor
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
HU222117B1 (en) 1992-01-27 2003-04-28 Janssen Pharmaceutica N.V. Pyrrolo [1,2-c] imidazolyl and imidazo[1,5-a]pyridinyl substituted 1h-benzimidazole derivatives, process for preparing them and pharmaceutical compositions containing them
ATE398124T1 (en) * 2002-11-18 2008-07-15 Novartis Pharma Gmbh IMIDAZOÄ1,5ÜA PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE-ASSOCIATED DISEASES
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
KR20090094374A (en) 2006-12-18 2009-09-04 노파르티스 아게 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2011064376A1 (en) 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
RS58234B1 (en) * 2010-01-14 2019-03-29 Novartis Ag Use of an adrenal hormone-modifying agent

Also Published As

Publication number Publication date
MX2014008686A (en) 2014-08-27
CY1117914T1 (en) 2017-05-17
EA201491374A1 (en) 2014-12-30
JP5749410B2 (en) 2015-07-15
PL2804863T3 (en) 2016-06-30
BR112014017260A8 (en) 2017-07-04
UA114803C2 (en) 2017-08-10
SG11201404061YA (en) 2014-08-28
CN104039793A (en) 2014-09-10
CU20140086A7 (en) 2014-12-26
ZA201404314B (en) 2015-08-26
RS54589B1 (en) 2016-08-31
HUE026984T2 (en) 2016-08-29
CL2014001863A1 (en) 2014-11-07
KR20140141687A (en) 2014-12-10
AP2014007762A0 (en) 2014-07-31
BR112014017260A2 (en) 2017-06-13
CR20140345A (en) 2014-09-09
IL233541B (en) 2018-12-31
SI2804863T1 (en) 2016-05-31
AU2013209952A1 (en) 2014-07-24
JO3137B1 (en) 2017-09-20
WO2013109514A1 (en) 2013-07-25
HRP20160178T1 (en) 2016-03-25
AU2013209952B2 (en) 2016-09-01
TWI609869B (en) 2018-01-01
ES2564143T8 (en) 2020-11-18
PE20142358A1 (en) 2015-01-30
PH12014501638A1 (en) 2014-10-13
PH12014501638B1 (en) 2014-10-13
US20140364470A1 (en) 2014-12-11
IL233541A0 (en) 2014-08-31
EA026232B1 (en) 2017-03-31
TW201335161A (en) 2013-09-01
EP2804863B1 (en) 2015-12-02
US9334276B2 (en) 2016-05-10
CA2863339A1 (en) 2013-07-25
SMT201600083B (en) 2016-04-29
JP2015503627A (en) 2015-02-02
NZ626277A (en) 2015-10-30
CO7000775A2 (en) 2014-07-21
GT201400155A (en) 2017-09-28
CN104039793B (en) 2017-05-10
AR089728A1 (en) 2014-09-10
UY34576A (en) 2013-09-02
KR20140093726A (en) 2014-07-28
MA35858B1 (en) 2014-12-01
HK1198536A1 (en) 2015-05-15
US20160176883A1 (en) 2016-06-23
ES2564143T3 (en) 2016-03-18
DK2804863T3 (en) 2016-03-07
CA2863339C (en) 2021-03-23
EP2804863A1 (en) 2014-11-26
TN2014000256A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
IN2014DN06781A (en)
HK1244483A1 (en) Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
HRP20182007T1 (en) 3-oxo-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine derivatives for the treatment of respiratory diseases
IL235659A (en) Substituted 3, 4 - dihydro-2h- pyrido [1, 2 - a] pyrazine -1, 6- dione derivatives useful for the treatment of (inter alia) alzheimer's disease
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
LT3808749T (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
IN2014DN07384A (en)
MX347917B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof.
UA115887C2 (en) Amino-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
GEP20156285B (en) Compounds and compositions as trk inhibitors
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
MX336332B (en) Kinase inhibitors, prodrug forms thereof and their use in therapy.
HK1177207A1 (en) 5-oxo-5, 8-dihydropyrido [2, 3-d]pyrimidine derivatives as camkii kinases inhibitors for the treatment of cardiovascular diseases camkii 5--58-[23-d]
TN2013000377A1 (en) Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia
MX2015005977A (en) Salt and polymorphic forms of (3r,4s)-l-((4-amino-5h-pyrrolo[3,2- d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(mtdia).
TN2013000483A1 (en) Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
TN2013000146A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof